PMID- 29137451
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 48
DP  - 2017 Oct 13
TI  - The transcription factor ATF5: role in cellular differentiation, stress 
      responses, and cancer.
PG  - 84595-84609
LID - 10.18632/oncotarget.21102 [doi]
AB  - Activating transcription factor 5 (ATF5) is a cellular prosurvival transcription 
      factor within the basic leucine zipper (bZip) family that is involved in cellular 
      differentiation and promotes cellular adaptation to stress. Recent studies have 
      characterized the oncogenic role of ATF5 in the development of several different 
      types of cancer, notably glioblastoma. Preclinical assessment of a systemically 
      deliverable dominant-negative ATF5 (dnATF5) biologic has found that targeting 
      ATF5 results in tumor regression and tumor growth inhibition of glioblastoma 
      xenografts in mouse models. In this review, we comprehensively and critically 
      detail the current scientific literature on ATF5 in the context of cellular 
      differentiation, survival, and response to stressors in normal tissues. 
      Furthermore, we will discuss how the prosurvival role of ATF5 aides in cancer 
      development, followed by current advances in targeting ATF5 using 
      dominant-negative biologics, and perspectives on future research.
FAU - Sears, Thomas K
AU  - Sears TK
AD  - Department of Molecular Biosciences, University of California, Davis School of 
      Veterinary Medicine, Davis, 95616 CA, USA.
FAU - Angelastro, James M
AU  - Angelastro JM
AD  - Department of Molecular Biosciences, University of California, Davis School of 
      Veterinary Medicine, Davis, 95616 CA, USA.
LA  - eng
GR  - P30 CA093373/CA/NCI NIH HHS/United States
GR  - R01 NS083795/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170920
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5663623
OTO - NOTNLM
OT  - ATF5
OT  - CP (cell penetrating peptide)
OT  - CP-d/n-ATF5 (cell penetrating peptide dominant negative ATF5)
OT  - ER stress
OT  - protein homeostasis
COIS- CONFLICTS OF INTEREST Dr. Angelastro currently holds several patents. These 
      patents pertain to the use of various dominant-negative ATF5 peptides as 
      anticancer agents. Dr. Angelastro holds United States patents US 07888326 and US 
      08158420 (Columbia University). Columbia University and University of California, 
      Davis jointly share a provisional patent application filed, February 22, 2013 
      (U.S. Provisional Application Serial No. 61/768,390). Dr. Angelastro is 
      Scientific advisory board member for Sapience Therapeutics. Sapience Therapeutics 
      holds technology licenses for ATF5 therapeutic targeting (Columbia University).
EDAT- 2017/11/16 06:00
MHDA- 2017/11/16 06:01
PMCR- 2017/10/13
CRDT- 2017/11/16 06:00
PHST- 2017/06/09 00:00 [received]
PHST- 2017/08/31 00:00 [accepted]
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/11/16 06:01 [medline]
PHST- 2017/10/13 00:00 [pmc-release]
AID - 21102 [pii]
AID - 10.18632/oncotarget.21102 [doi]
PST - epublish
SO  - Oncotarget. 2017 Sep 20;8(48):84595-84609. doi: 10.18632/oncotarget.21102. 
      eCollection 2017 Oct 13.